A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period
VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome, Followed by an Open-Label Extension Period
The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
This is a randomized, double-blind, placebo-controlled study with a 52-week duration evaluating the efficacy and safety of arumakimig in participants with VEXAS who are receiving glucocorticoids. Participants will be randomized 1:1 to either arumakimig or placebo.
Following the double-blind period, participants may have the option to enter a 2-year (104-week) open-label extension (OLE) period, continuing until Week 156.
A 16-week safety follow-up period must be completed after the OLE (up to Week 172) or after the double-blind period (up to Week 68).
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Sauvegarde des contacts de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: +41613241111
Lieux d'étude
-
-
-
Fukushima, Japon, 9601295
- Recrutement
- Novartis Investigative Site
-
Niigata, Japon, 9518520
- Recrutement
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Japon, 2360004
- Recrutement
- Novartis Investigative Site
-
-
Osaka
-
Suita, Osaka, Japon, 5650871
- Recrutement
- Novartis Investigative Site
-
-
Tokyo
-
Hachiōji, Tokyo, Japon, 1930998
- Recrutement
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Japon, 1608582
- Recrutement
- Novartis Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male and female participants aged ≥18 years at screening.
- Somatic mutation in UBA1 gene known to be associated with VEXAS.
- Participants must have at least two manifestations of VEXAS at screening or in the past 6 months.
- Participants must be able to start treatment for Pneumocystis jiroveci pneumonia (PJP) during the study if indicated according to the local guidelines.
- Ability to communicate well with the Investigator, understand and agree to comply with the requirements of the study.
Exclusion Criteria:
- Participants meeting any of the following criteria are not eligible for this study:
- Positive serology for hepatitis B surface antigen (HBsAg) excludes the participant.
HBsAg negative participants who are hepatitis B core antibody (HBcAb) positive are also excluded unless protocol-defined criteria are met.
- Participants with a positive HCV antibody test should have HCV ribonucleic acid (RNA) levels measured. Participants with positive (detectable) HCV RNA must be excluded. Chronic hepatitis C patients who have completed HCV anti-viral treatment must be HCV-RNA negative at least 12 weeks after treatment before randomization to be eligible.
- Active viral, bacterial, or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infections.
- Known or suspected Human Immunodeficiency Virus (HIV) infection. Should it be required by local regulations and/or considered appropriate by the Investigator, an HIV test can be performed locally to confirm eligibility.
- Live vaccinations within a certain period prior to arumakimig treatment. Live vaccines are prohibited during the trial and up to a certain period following the last dose of arumakimig.
- History of malignancy of any organ system, including post-transplant lymphoproliferative disorder (except for skin Bowen's disease, completely treated and resolved, localized squamous or basal cell carcinoma of the skin or actinic keratosis that have been treated with no evidence of recurrence in the past 12 weeks, in situ cervical cancer or non-invasive malignant colon polyps that have been removed), treated or untreated, within a protocol-defined period, regardless of whether there is evidence of local recurrence or metastases.
- History of or current hepatic disease (moderate to severe Hepatic Impairment as per Child-Pugh classification), including but not limited to, acute or chronic hepatitis (for Hepatitis B or C), cirrhosis or hepatic failure.
- Participants of child-bearing potential who do not agree to comply with required contraceptive use as outlined in the protocol.
Other protocol-defined inclusion/exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Arumakimig
Arumakimig from Day 1 to Week 52 during the double-blind period. Eligible participants may then continue into an open-label extension and receive arumakimig through Week 156. |
Arumakimig Injection
Autres noms:
Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement. |
|
Comparateur placebo: Placebo
Placebo from Day 1 to Week 52 during the double-blind period. Eligible participants may then continue into an open-label extension and receive arumakimig through Week 156. |
Arumakimig Injection
Autres noms:
Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement. Placebo Injection |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants achieving improvement of key VEXAS manifestations and oral glucocorticoid (GC) reduction at Week 52
Délai: From baseline up to Week 52
|
Response is defined as meeting both criteria: A) Clinical domain: In participants with clinical disease activity in any domain at baseline, complete resolution of clinical manifestations related to active disease in at least one affected domain. In participants with no clinical disease activity in any domain at baseline, continued absence of clinical manifestations in all domains at Week 52. AND B) Protocol-defined glucocorticoid reduction through 52 weeks. |
From baseline up to Week 52
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants achieving Overall Clinical Response (OCR) at Week 52
Délai: From baseline up to Week 52
|
Achieving OCR at Week 52 is defined as meeting all the following criteria:
|
From baseline up to Week 52
|
|
Number of participants achieving resolution of VEXAS manifestations
Délai: From baseline up to Week 52
|
In participants with clinical disease activity in any domain at baseline, achieving complete resolution of clinical manifestations. |
From baseline up to Week 52
|
|
Number of participants with oral glucocorticoid reduction
Délai: From baseline up to Week 52
|
Number of participants achieving protocol-defined glucocorticoid dose reduction through 52 weeks. |
From baseline up to Week 52
|
|
Total number of flare-free days over 52 weeks
Délai: Up to 52 weeks
|
Total cumulative number of days over 52 weeks meeting the protocol-defined criteria for a flare-free day. |
Up to 52 weeks
|
|
Number of participants achieving Hematologic Improvement - Erythroid (HI-E) during the double-blind treatment period
Délai: From baseline up to Week 52
|
Hematologic Improvement - Erythroid (HI-E) during the double-blind 52-week treatment period among participants with baseline hemoglobin within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria. |
From baseline up to Week 52
|
|
Number of participants achieving Hematologic Improvement - Platelets (HI-P) during the double-blind treatment period
Délai: From baseline up to Week 52
|
Hematologic Improvement - Platelets (HI-P) during the double-blind 52-week treatment period among participants with baseline platelets within the protocol-defined range, according to modified International Working Group (IWG) and protocol-defined response criteria. |
From baseline up to Week 52
|
|
Number of participants without worsening disease according to a participant-reported questionnaire
Délai: From baseline up to Week 52
|
Participants without protocol-defined worsening of disease according to a participant-reported questionnaire. |
From baseline up to Week 52
|
|
Time to death during the double-blind treatment period
Délai: Up to 52 weeks
|
Assessment of mortality through Week 52 in each treatment arm. |
Up to 52 weeks
|
|
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Délai: Up to 172 weeks
|
Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms and laboratory values qualifying and reported as AEs. |
Up to 172 weeks
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Maladies musculo-squelettiques
- Maladies articulaires
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Arthrite
- Arthralgie
- Syndrome de Vexas
- Effets physiologiques des drogues
- Hormones
- Hormones, substituts hormonaux et antagonistes hormonaux
- Actions pharmacologiques
- Actions et utilisations chimiques
- Hormones cortex surrénaliques
- Glucocorticoïdes
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- CMAS825G12203
- 2026-527354-39 (Identificateur de registre: EU CTIS)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .